Stumbar SE, Stevens M, Feld Z. Cervical cancer and its precursors: a preventative approach to screening, diagnosis, and management. Prim Care. 2019;46(1):117–34.
Article
PubMed
Google Scholar
Canadian Cancer Society. Cervical cancer. 2019. https://www.cancer.ca/en/cancer-information/cancer-type/cervical/cervical-cancer/?region=on. Accessed 5 Jun 2020.
Google Scholar
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.
Article
CAS
PubMed
Google Scholar
Volesky KD, El-Zein M, Franco EL, Brenner DR, Friedenreich CM, Ruan Y, et al. Cancers attributable to infections in Canada. Prev Med. 2019;122:109–17.
Article
PubMed
Google Scholar
Herrero R. Cervical cancer. In: Thun MJ, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D, editors. Cancer epidemiology and prevention. 4th ed. New York: Oxford University Press; 2018. p. 925–46.
Google Scholar
Canadian Cancer Society. HPV and cancer. 2019. https://www.cancer.ca/en/prevention-and-screening/reduce-cancer-risk/make-informed-decisions/get-vaccinated/hpv-and-cancer/?region=on. Accessed 5 Jun 2020.
Google Scholar
Tricco AC, Ng CH, Gilca V, Anonychuk A, Pham B, Berliner S. Canadian oncogenic human papillomavirus cervical infection prevalence: systematic review and meta-analysis. BMC Infect Dis. 2011;11:235.
Article
PubMed
PubMed Central
Google Scholar
Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–4.
Article
PubMed
PubMed Central
Google Scholar
World Health Organization. Human papillomavirus (HPV) and cervical cancer. 2019. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer. Accessed 5 Jun 2020.
Google Scholar
Ramirez PT, Salvo G. Cervical cancer: Merck manual. 2019. https://www.merckmanuals.com/en-ca/home/women-s-health-issues/cancers-of-the-female-reproductive-system/cervical-cancer. Accessed 5 Jun 2020.
Google Scholar
Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003;31:14–9.
Article
Google Scholar
Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer. 2009;4:8.
Article
PubMed
PubMed Central
CAS
Google Scholar
Coutlée F, Ratnam S, Ramanakumar AV, Insinga RR, Bentley J, Escott N, et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol. 2011;83(6):1034–41.
Article
PubMed
Google Scholar
Jaisamrarn U, Castellsagué X, Garland SM, Naud P, Palmroth J, Del Rosario-Raymundo MR, et al. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One. 2013;8(11):e79260.
Article
PubMed
PubMed Central
CAS
Google Scholar
Bernard E, Pons-Salort M, Favre M, Heard I, Delarocque-Astagneau E, Guillemot D, et al. Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: a meta-analysis of observational studies. BMC Infect Dis. 2013;13:373.
Article
PubMed
PubMed Central
Google Scholar
Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cárdenas J, Glazer-Livson S, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018;360:k499.
Article
PubMed
PubMed Central
Google Scholar
McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425–34.
Article
PubMed
Google Scholar
McIndoe WA, McLean MR, Jones RW, Mullins PRJOG. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol. 1984;64(4):451–8.
CAS
PubMed
Google Scholar
Hildesheim A, Hadjimichael O, Schwartx PE, Wheeler CM, Barnes W, Lowell DM, et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol. 1999;180(3 Pt 1):571–7.
Article
CAS
PubMed
Google Scholar
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890–907.
Article
CAS
PubMed
Google Scholar
Fu T-CJ, Carter JJ, Hughes JP, Feng Q, Hawes SE, Schwartz SM, et al. Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women. Int J Cancer. 2016;139(10):2201–12.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shew ML, Ermel AC, Tong Y, Tu W, Qadadri B, Brown DR. Episodic detection of human papillomavirus within a longitudinal cohort of young women. J Med Virol. 2015;87(12):2122–9.
Article
PubMed
Google Scholar
Liu S-H, Cummings DAT, Zenilman JM, Gravitt PE, Brotman RM. Characterizing the temporal dynamics of human papillomavirus DNA detectability using short-interval sampling. Cancer Epidemiol Biomark Prev. 2014;23(1):200–8.
Article
CAS
Google Scholar
Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181(6):1911–9.
Article
CAS
PubMed
Google Scholar
Gravitt PE. Evidence and impact of human papillomavirus latency. Open Virol J. 2012;6:198–203.
Article
PubMed
PubMed Central
Google Scholar
Public Health England. NHS cervical screening programme. In: Colposcopy and Programme Management, The National Health Service. 3rd ed; 2016. https://www.bsccp.org.uk/assets/file/uploads/resources/NHSCSP_20_Colposcopy_and_Programme_Management_(3rd_Edition)_(2).pdf. Accessed 5 Jun 2020.
Google Scholar
National Cancer Institute. NCI dictionary of cancer terms. 2020. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/invasive-cervical-cancer. Accessed 5 Jun 2020.
Google Scholar
Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev. 2013;2:35.
Article
PubMed
PubMed Central
Google Scholar
Smith JHF, Patnik J. Achievable standards, benchmarks for reporting, and criteria for evaluating cervical cytopathology. 3rd ed. Sheffield: NHS Cancer Screening Programmes; 2013.
Google Scholar
Nayar R, Wilbur DC. The pap test and Bethesda 2014. Acta Cytol. 2015;59(2):121–32.
Article
CAS
PubMed
Google Scholar
Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2013;32(1):76–115.
Article
PubMed
Google Scholar
Sellors JW, Sankaranarayanan R. Colposcopy and treatment of cervical intraepithelial neoplasia: a beginner’s manual. London: Diamond Pocket Books Ltd; 2003.
Google Scholar
Brenner DR, Weir HK, Demers AA, Ellison LF, Louzado C, Shaw A, et al. Projected estimates of cancer in Canada in 2020. CMAJ. 2020;192(9):e199–205.
Article
PubMed
PubMed Central
Google Scholar
The International Collaboration of Epidemiological Studies of Cervical, C., Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120(4):885-91.
Navaneelan, T. Trends in the incidence and mortality of female reproductive system cancers. Health at a Glance. Statistics Canada Catologue no 82-624-X. 2015. https://www150.statcan.gc.ca/n1/pub/82-624-x/2015001/article/14095-eng.htm. Accessed 5 Jun 2020.
Google Scholar
Popadiuk C, Stankiewicz A, Dickinson J, Pogany L, Miller AB, Onysko J. Invasive cervical cancer incidence and mortality among canadian women aged 15 to 29 and the impact of screening. J Obstet Gynaecol Can. 2012;34(12):1167–76.
Article
PubMed
Google Scholar
Canadian Cancer Statistics Advisory Committee. Canadian cancer statistics 2018. Toronto: Canadian Cancer Society; 2018. https://cancer.ca/Canadian-Cancer-Statistics-2018-EN. Acccessed 5 Jun 2020.
Google Scholar
Benard VB, Watson M, Saraiya M, Harewood R, Townsend JS, Stroup AM, et al. Cervical cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study. Cancer. 2017;123(Suppl 24):5119–37.
Article
PubMed
Google Scholar
Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction—the first five years. Vaccine. 2012;30:F139–F48.
Article
PubMed
Google Scholar
Public Health Agency of Canada. Canadian immunization guide: part 4—active vaccines. 2018. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines.html. Accessed 5 Jun 2020.
Google Scholar
Kreimer AR, Rolando H, Sampson JN, Porras C, Lowy DR, Schiller JT, et al. Evidence for single-dose protection by the bivalent HPV vaccine—review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018;36(32, Part A):4774–82.
Article
PubMed
PubMed Central
Google Scholar
Arbyn M, Xu L, Simoens C, Martin-Hirsch PPL. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5(5):CD009069.
PubMed
Google Scholar
Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev. 2019;11:CD013479.
Google Scholar
Canadian Partnership Against Cancer. Cervical cancer screening in Canada: environmental scan. Toronto: Canadian Partnership Against Cancer; 2018.
Google Scholar
Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):e20151968.
Article
PubMed
Google Scholar
Steben M, Tan Thompson M, Rodier C, Mallette N, Racovitan V, DeAngelis F, et al. A review of the impact and effectiveness of the quadrivalent human papillomavirus vaccine: 10 years of clinical experience in Canada. J Obstet Gynaecol Can. 2018;40(12):1635–45.
Article
PubMed
Google Scholar
Kitchener H. Optimising future cervical screening strategies. Papillomavirus Res. 2019;7:201–3.
Article
PubMed
PubMed Central
Google Scholar
Volesky KD, El-Zein M, Franco EL, Brenner DR, Friedenreich CM, Ruan Y, et al. Estimates of the future burden of cancer attributable to infections in Canada. Prev Med. 2019;122:118–27.
Article
PubMed
Google Scholar
El-Zein M, Richardson L, Franco EL. Cervical cancer screening of HPV vaccinated populations: cytology, molecular testing, both or none. J Clin Virol. 2016;76(Suppl 1):S62–S8.
Article
PubMed
Google Scholar
Maxim LD, Niebo R, Utell MJ. Screening tests: a review with examples. Inhal Toxicol. 2014;26(13):811–28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Landy R, Windridge P, Gillman MS, Sasieni PD. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. Int J Cancer. 2018;142(4):709–18.
Article
CAS
PubMed
Google Scholar
Shaw PA. The history of cervical screening I: the pap. test. 2000;22(2):110–4.
Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PPL, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017;8(8):CD008587.
PubMed
Google Scholar
Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018;320(1):43–52.
Article
PubMed
PubMed Central
Google Scholar
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249–57.
Article
CAS
PubMed
Google Scholar
Leinonen MK, Nieminen P, Lonnberg S, Malila N, Hakama M, Pokhrel A, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ. 2012;345:e7789.
Article
PubMed
PubMed Central
CAS
Google Scholar
Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial. PLoS Med. 2017;14(9):e1002388.
Article
PubMed
PubMed Central
Google Scholar
Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006;7(7):547–55.
Article
PubMed
Google Scholar
Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78–88.
Article
PubMed
Google Scholar
Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589–97.
Article
CAS
PubMed
Google Scholar
Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672–82.
Article
PubMed
Google Scholar
Poli UR, Gowrishankar S, Swain M, Jeronimo J. Triage of women testing positive with the careHPV test on self-collected vaginal samples for cervical cancer screening in a low-resource setting. J Glob Oncol. 2018;4:1–7.
PubMed
Google Scholar
Chao YS, Clark M, Carson E, Weeks L, Moulton K, McFaul S, McLauchlin CM. HPV Testing for primary cervical cancer screening: a health technology assessment. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019.
Google Scholar
Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ. 2014;349:g5264.
Article
PubMed
PubMed Central
CAS
Google Scholar
Cook DA, Smith LW, Law JH, Mei W, Gondara L, van Niekerk DJ, et al. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial. J Clin Virol. 2018;108:32–7.
Article
CAS
PubMed
Google Scholar
Iftner T, Becker S, Neis K-J, Castanon A, Iftner A, Holz B, et al. Head-to-head comparison of the RNA-based aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. J Clin Microbiol. 2015;53(8):2509.
Article
CAS
PubMed
PubMed Central
Google Scholar
Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(7):687–705.
Article
PubMed
Google Scholar
Hakama M, Chamberlain J, Day NE, Miller AB, Prorok PC. Evaluation of screening programmes for gynaecological cancer. Br J Cancer. 1985;52(4):669–73.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hakama M. Screening for cervical cancer: experience of the Nordic countries. In: Franco E, Monsonego J, editors. New developments in cervical cancer screening and prevention. Oxford: Blackwell Science; 1997. p. 190–9.
Google Scholar
Canadian Partnership Against Cancer. Cervical cancer screening in Canada: environmental scan. Toronto: Canadian Partnership Against Cancer; 2018. https://www.partnershipagainstcancer.ca/topics/cervical-cancer-screening-environmental-scan-2018/#0. Accessed 5 Jun 2020.
Google Scholar
Zhang Y, Coello PA, Brozek J, Wiercioch W, Etxeandia-Ikobaltzeta I, Akl EA, et al. Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach. Health Qual Life Outcomes. 2017;15(1):52.
Article
PubMed
PubMed Central
Google Scholar
Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(7):674–86.
Article
PubMed
Google Scholar
Statistics Canada. Health fact sheets: cancer screening, 2017. Ottawa: Government of Canada; 2018. https://www150.statcan.gc.ca/n1/pub/82-625-x/2018001/article/54977-eng.htm. Accessed 5 Jun 2020.
Google Scholar
Ahmed S, Shahid RK, Episkenew JA. Disparity in cancer prevention and screening in aboriginal populations: recommendations for action. Curr Oncol. 2015;22(6):417–26.
Article
CAS
PubMed
PubMed Central
Google Scholar
Elit L, Krzyzanowska M, Saskin R, Barbera L, Razzaq A, Lofters A, et al. Sociodemographic factors associated with cervical cancer screening and follow-up of abnormal results. Can Fam Physician. 2012;58(1):e22.
PubMed
PubMed Central
Google Scholar
Farley M, Golding JM, Minkoff JR. Is a history of trauma associated with a reduced likelihood of cervical cancer screening? J Fam Pract. 2002;51(10):827–31.
PubMed
Google Scholar
Kouyoumdjian FG, McConnon A, Herrington ERS, Fung K, Lofters A, Hwang SW. Cervical cancer screening access for women who experience imprisonment in Ontario, Canada. JAMA Netw Open. 2018;1(8):e18563.
Article
Google Scholar
Kerner J, Liu J, Wang K, Fung S, Landry C, Lockwood G, et al. Canadian cancer screening disparities: a recent historical perspective. Curr Oncol. 2015;22(2):156–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Committee on Health Care for Underserved Women. Committee Opinion no. 512: health care for transgender individuals. Obstet Gynecol. 2011;118(6):1454–8.
Article
Google Scholar
Canadian Task Force on Preventive Health C. Recommendations on screening for cervical cancer. CMAJ. 2013;185(1):35–45.
Article
Google Scholar
Health PEI. Cervical cancer screening. Staff Resource Centre. 2020. https://src.healthpei.ca/cervical-cancer-screening. Accessed 5 Jun 2020.
Google Scholar
Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National Cervical Screening Program: guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Sydney: Cancer Council Australia; 2016.
Google Scholar
United Kingdom National Screening Committee. The UK NSC recommendation on cervical cancer screening in women. 2016. https://legacyscreening.phe.org.uk/cervicalcancer. Accessed 5 Jun 2020.
Google Scholar
van Ballegooijen M, Hermens R. Cervical cancer screening in the Netherlands. Eur J Cancer. 2000;36(17):2244–6.
Article
PubMed
Google Scholar
Canadian Task Force on Preventive Health Care. Procedure manual: Canadian Task Force on Preventive Health Care. 2014. https://canadiantaskforce.ca/wp-content/uploads/2016/12/procedural-manual-en_2014_Archived.pdf. Accessed 5 Jun 2020.
Google Scholar
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
Article
PubMed
PubMed Central
Google Scholar
Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395–400.
Article
PubMed
Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
Article
PubMed
PubMed Central
Google Scholar
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100(7):492–501.
Article
PubMed
Google Scholar
Ogilvie GS, van Niekerk DJ, Krajden M, Martin RE, Ehlen TG, Ceballos K, et al. A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer. 2010;10:111.89.
Article
Google Scholar
Cook DA, Mei W, Smith LW, van Niekerk DJ, Ceballos K, Franco EL, et al. Comparison of the Roche cobas(R) 4800 and Digene Hybrid Capture(R) 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer. 2015;15:968.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ogilvie GS, Krajden M, van Niekerk D, Smith LW, Cook D, Ceballos K, et al. HPV for cervical cancer screening (HPV FOCAL): complete round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. Int J Cancer. 2017;140(2):440–8.
Article
CAS
PubMed
Google Scholar
Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006;98(11):765–74.
Article
PubMed
Google Scholar
Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer. 2004;110(1):94–101.
Article
CAS
PubMed
Google Scholar
Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ. 2016;355:i4924.
Article
PubMed
Google Scholar
Elfstrom KM, Smelov V, Johansson AL, Eklund C, Naucler P, Arnheim-Dahlstrom L, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ. 2014;348:g130.
Article
PubMed
PubMed Central
Google Scholar
Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P. The psychosocial impact of human papillomavirus testing in primary cervical screening-a study within a randomized trial. Int J Gynecol Cancer. 2008;18(4):743–8.
Article
CAS
PubMed
Google Scholar
Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13(51):1–150, iii-iv.
Article
CAS
PubMed
Google Scholar
Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess. 2014;18(23):1–196.
Article
Google Scholar
Kyrgiou M, Mitra A, Arbyn M, Paraskevaidi M, Athanasiou A, Martin-Hirsch PPL, et al. Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2015;9:CD008478.
Google Scholar
Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin-Hirsch PPL, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev. 2017;11:CD012847.
PubMed
Google Scholar
Zhang Y, Alonso-Coello P, Guyatt GH, Yepes-Nunez JJ, Akl EA, Hazlewood G, et al. GRADE Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences—risk of bias and indirectness. J Clin Epidemiol. 2019;111:94–104.
Article
PubMed
Google Scholar
Zhang Y, Coello PA, Guyatt GH, Yepes-Nunez JJ, Akl EA, Hazlewood G, et al. GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences-inconsistency, imprecision, and other domains. J Clin Epidemiol. 2019;111:83–93.
Article
PubMed
Google Scholar
Robinson KA, Chou R, Berkman ND, Newberry SJ, Fu R, Hartling L, et al. Twelve recommendations for integrating existing systematic reviews into new reviews: EPC guidance. J Clin Epidemiol. 2016;70:38–44.
Article
PubMed
Google Scholar
McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40–6.
Article
PubMed
Google Scholar
Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823.
Article
PubMed
PubMed Central
Google Scholar
Everett T, Bryant A, Griffin MF, Martin-Hirsch PP, Forbes CA, Jepson RG. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Rev. 2011;5:CD002834.
Google Scholar
Khangura S, Konnyu K, Cushman R, Grimshaw J, Moher D. Evidence summaries: the evolution of a rapid review approach. Syst Rev. 2012;1(1):10.
Article
PubMed
PubMed Central
Google Scholar
O’Blenis P. One simple way to speed up your screening process. 2017. https://blog.evidencepartners.com/one-simple-way-to-speed-up-your-screening-process. Accessed 5 Jun 2020.
Google Scholar
Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol. 2008;8(1):45.
Article
PubMed
PubMed Central
Google Scholar
Page MJ, McKenzie JE, Higgins JPT. Tools for assessing risk of reporting biases in studies and syntheses of studies: a systematic review. BMJ Open. 2018;8(3):e019703.
Article
PubMed
PubMed Central
Google Scholar
Farrah K, Young K, Tunis MC, Zhao L. Risk of bias tools in systematic reviews of health interventions: an analysis of PROSPERO-registered protocols. Syst Rev. 2019;8(1):280.
Article
PubMed
PubMed Central
Google Scholar
Quigley JM, Thompson JC, Halfpenny NJ, Scott DA. Critical appraisal of nonrandomized studies—a review of recommended and commonly used tools. J Eval Clin Pract. 2019;25(1):44–52.
Article
PubMed
Google Scholar
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Article
PubMed
PubMed Central
Google Scholar
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2019. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 5 Jun 2020.
Google Scholar
Cochrane Effective Practice and Organisation of Care. Suggested risk of bias criteria for EPOC reviews. 2019. https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-for-authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf. Accessed 5 Jun 2020.
Google Scholar
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36.
Article
PubMed
Google Scholar
Critical Appraisals Skills Programme. CASP Checklists. 2018. https://casp-uk.net/casp-tools-checklists/. Accessed 5 Jun 2020.
Google Scholar
Higgins JPT, Tianjing L, Deeks JD. Chapter 6: choosing effect measures and computing estimates of effect. In: Higgins JPT, Tianjing L, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions, version 6.0. Cochrane; 2019.
Chapter
Google Scholar
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
Article
CAS
PubMed
Google Scholar
Deeks JJ, Higgins JPT, Altman DG. Chapter 10: analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions, version 6.0. Cochrane; 2019.
Google Scholar
Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23(9):1351–75.
Article
PubMed
Google Scholar
Schunemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH. Chapter 14: Completing ‘summary of findings’ tables and grading the certainty of evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions, version 6.0. Cochrane; 2019.
Google Scholar
Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001;20(19):2865–84.
Article
CAS
PubMed
Google Scholar
Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10: Analysing and presenting results. In: Deeks JJ, Bossuyt PM, Gatsonis C, editors. Cochrane handbook for systematic reviews of diagnostic test accuracy, version 1.0. The Cochrane Collaboration; 2010.
Google Scholar
Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews. A product from the ESRC Methods Programme. 2006;1:b92.
Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398–405.
Article
PubMed
Google Scholar
Higgins JPT, Eldridge S, Li T. Chapter 23: Including variants on randomized trials. In: Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions, version 6.0. Cochrane; 2019.
Chapter
Google Scholar
Rao JN, Scott AJ. A simple method for the analysis of clustered binary data. Biometrics. 1992;48(2):577–85.
Article
CAS
PubMed
Google Scholar
Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health. 2019;7(2):192–8.
Article
Google Scholar
Oxman AD, Guyatt GH. A consumer’s guide to subgroup analyses. Ann Intern Med. 1992;116(1):78–84.
Article
CAS
PubMed
Google Scholar
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schunemann H, Brozek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations: The GRADE Working Group; 2013. https://gdt.gradepro.org/app/handbook/handbook.html. Accessed 5 Jun 2020.
Murad MH, Mustafa RA, Schunemann HJ, Sultan S, Santesso N. Rating the certainty in evidence in the absence of a single estimate of effect. Evid Based Med. 2017;22(3):85–7.
Article
PubMed
PubMed Central
Google Scholar
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
Article
PubMed
Google Scholar
Guyatt GH, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.
Article
PubMed
Google Scholar
Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol. 2011;64(12):1277–82.
Article
PubMed
Google Scholar
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol. 2011;64(12):1294–302.
Article
PubMed
Google Scholar
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin Epidemiol. 2011;64(12):1303–10.
Article
PubMed
Google Scholar
Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol. 2011;64(12):1283–93.
Article
PubMed
Google Scholar
Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.
Article
PubMed
Google Scholar
Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol. 2020;122:129–41.
Article
PubMed
Google Scholar
Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol. 2020;122:142–52.
Article
PubMed
Google Scholar
Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et al. The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017;87:4–13.
Article
PubMed
PubMed Central
Google Scholar
Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719–25.
Article
PubMed
Google Scholar